Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Celularity Inc.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.

Dragasac Limited

Sorrento Therapeutics

Starr Insurance Companies

Alumni Ventures

Heritage Group

Human Longevity

Section 32 Celgene

United Therapeutics

Bill Maris

Tony Robbins

We're excited for the future here at Celularity and are off to an invigorating 2024! Net sales expectations and updates can be found in the full release, linked below.

Exciting announcement! The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions.

Excited about the future at Celularity!
https://lnkd.in/gmJmRJCP

We're pleased to have had our Chairman, CEO and Founder, Dr. Bob Hariri, featured by Cell & Gene .  Discussion topics included lessons learned in allogeneic cell therapy, advice for allogeneic cell therapy start-ups, the strategy behind the Celularity facility, and more. 
#celltherapy #cellandgenetherapy 
https://lnkd.in/dj2Sr_3c

We’re pleased to announce our exclusive U.S. commercialization agreement with Verséa Health (Verséa Ophthalmics), which will allow us to support eye care professionals as they treat ocular surface diseases and perform certain ocular surgeries. Discover more about the partnership: https://bit.ly/3YcZdOM

Next Wednesday, July 26, our team will present data on Celularity’s proprietary #biomaterials at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE) in Osaka, Japan.

Presented by Anna Gosiewska, PhD, the data will include three benchtop and clinical case studies for three Celularity human placental-derived advanced biomaterial products. Find out more about the data here: https://bit.ly/3JY4LXS

Check out this interview with our Chairman, CEO and Founder, Dr. Bob Hariri, in the latest issue of Pulse 2.0
https://lnkd.in/ejr2bu6X

Next month, Celularity will present at the 7th International Conference on Orthopedics in Rome. The oral session will share data from a new technology in development for orthopedic applications.
 
Read the full announcement to learn more about the study: https://bit.ly/3NpgMGA

Exciting update: data featured in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor (TF) gene knock out (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower TF expression, activity, and thrombotic effects. This #preclinical #data from an edited version of one of our cell therapy candidates signals a feasible pathway to potentially improve the safety of ASC-based #celltherapy.
 
Full details here: https://bit.ly/3qjvHua

Today, we are excited to announce that we have received a $45 million purchase order for Celularity private label Halal-Certified #biomaterial products from Jamjoom Medicine Store.
 
This marks the first purchase order received under our recently announced expansion into the Middle East market, as part of our global market strategy. Read the full announcement: https://bit.ly/426nqXw

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	5.88M -	-208.23M 3,642.12%	-100.12M 51.92%	14.19M 114.18%	-196.29M 1,483.14%
depreciation and amortization	6.19M -	8.17M 32.14%	8.82M 7.87%	9.44M 7.02%	9.32M 1.19%
deferred income tax	-1.65K -	-8.48M 513,027.65%	-1.35M 84.05%	-1K 99.93%
stock based compensation	3.67M -	4.37M 19.17%	40.01M 815.35%	15.86M 60.37%	15.02M 5.29%
change in working capital	136.39K -	3.60M 2,542.44%	-11.08M 407.52%	-17.98M 62.19%	3.25M 118.09%
accounts receivables	134K -	1.65M 1,132.84%	-1.91M 215.56%	-3.58M 87.74%	-6.83M 90.49%
inventory	-1.71M -	-643K 62.35%	-6.42M 898.76%	-16.89M 163.02%	-865K 94.88%
accounts payables	18.88K -	314K 1,562.87%	3.01M 857.64%	-2.95M 198.04%	8.50M 388.23%
other working capital	1.69M -	2.28M 34.85%	-5.76M 352.48%	5.45M 194.58%	1.80M 66.90%
other non cash items	-16.97M -	137.37M 909.73%	-46.37M 133.75%	-159.38M 243.73%	-94.47M 40.73%
net cash provided by operating activities	-1.10M -	-63.19M 5,656.16%	-110.10M 74.22%	-137.88M 25.23%	-38.69M 71.94%
investments in property plant and equipment	-31.57M -	-27.83M 11.85%	-6.20M 77.71%	-5.24M 15.59%	-4.05M 22.69%
acquisitions net		15.02M -
purchases of investments	-287.50M -
sales maturities of investments
other investing activites	32.23M -		300K -		-3M -
net cash used for investing activites	-286.85M -	-12.81M 95.53%	-5.90M 53.94%	-5.24M 11.30%	-4.05M 22.69%
debt repayment	-150K -		-5M -	-39.20M 684%	-3.56M 90.92%
common stock issued	288.99M -	102.67M 64.47%	83.40M 18.77%	36.52M 56.21%	21.89M 40.07%
common stock repurchased		-256K -		-132K -
dividends paid				-39.07M -
other financing activites	119.25M -	-403K 100.34%	20.16M 5,102.98%	161.72M 702.10%	-1.65M 101.02%
net cash used provided by financing activities	288.84M -	102.01M 64.68%	98.56M 3.38%	119.84M 21.59%	24.09M 79.89%
effect of forex changes on cash	20.09M -
net change in cash	892.30K -	26.01M 2,814.49%	-17.44M 167.05%	-23.27M 33.47%	-18.64M 19.91%
cash at beginning of period	24.71K -	43.51M 175,991.80%	69.51M 59.77%	52.08M 25.08%	28.80M 44.69%
cash at end of period	917.01K -	69.51M 7,480.42%	52.08M 25.08%	28.80M 44.69%	10.16M 64.71%
operating cash flow	-1.10M -	-63.19M 5,656.16%	-110.10M 74.22%	-137.88M 25.23%	-38.69M 71.94%
capital expenditure	-31.57M -	-27.83M 11.85%	-6.20M 77.71%	-5.24M 15.59%	-4.05M 22.69%
free cash flow	-32.67M -	-91.03M 178.60%	-116.30M 27.76%	-143.11M 23.06%	-42.73M 70.14%

COM:CELULARITY

Celularity Inc.

Last Close

2.85

22/11 21:00

Market Cap

61.43M

Beta: -

Volume Today

104.87K

Avg: -

Preview